论文部分内容阅读
目的观察盐酸羟考酮控释片治疗介入科癌痛患者的镇痛疗效及安全性。方法65例恶性肿瘤伴疼痛者,用数字评分法评估疼痛程度,根据介入科急慢性癌痛患者的疼痛程度,应用盐酸羟考酮控释片进行镇痛治疗,观察镇痛疗效、生活质量及不良反应。结果镇痛疗效:治疗前NRS评分6.87±1.21,治疗3、7、10 d分别为3.08±1.32、2.32±1.16和2.02±1.12,总有效率96.9%。治疗前后疼痛程度比较差异有显著性(P<0.001)。生活质量:治疗前生活质量良好的病例占43.1%,治疗后第7天和第10天分别增至70.8%和78.5%,治疗前后生活质量差异有显著性(P<0.01)。不良反应总发生率为35.4%,多为轻度,且持续时间较短,依次为便秘16例(24.6%),恶心呕吐10例(15.4%),头晕嗜睡6例(9.2%),无呼吸抑制等不能耐受的严重不良反应。结论针对介入科急慢性癌痛患者,盐酸羟考酮控释片是镇痛疗效好、安全性高的良好用药。
Objective To observe the analgesic efficacy and safety of oxycodone hydrochloride controlled-release tablets in the treatment of patients with cancer patients with cancer. Methods Sixty-five patients with malignant tumors and pain were evaluated by digital scoring method. According to the degree of pain in patients with acute and chronic cancer pain, the patients were treated with oxycodone hydrochloride controlled release tablets for analgesic therapy. Analgesic efficacy, quality of life, Adverse reactions. Results Analgesic efficacy: The pre-treatment NRS score was 6.87 ± 1.21, and the third, seventh and tenth days were 3.08 ± 1.32, 2.32 ± 1.16 and 2.02 ± 1.12 respectively, with a total effective rate of 96.9%. There was significant difference in the degree of pain before and after treatment (P <0.001). Quality of life: 43.1% of patients had good quality of life before treatment, 70.8% and 78.5% on day 7 and 10 after treatment, respectively. There was a significant difference in quality of life before and after treatment (P <0.01). The total incidence of adverse reactions was 35.4%, mostly mild and short duration, followed by constipation in 16 cases (24.6%), nausea and vomiting in 10 cases (15.4%), dizziness and drowsiness in 6 cases (9.2% Inhibition can not tolerate the serious adverse reactions. Conclusions Oxycodone hydrochloride controlled-release tablets are good and analgesic drugs with good analgesic efficacy and safety for patients with acute and chronic cancer pain who are involved in the department.